PROTEOSTASIS THERAPEUTICS, INC. Contracts & Agreements

Separation Agreement by and between Kineta, Inc. and Shawn Iadonato, Ph.D., dated March 1, 2024 (Filed With SEC on February 29, 2024)

Separation Agreement by and between Kineta, Inc. and Pauline Kenny, dated March 1, 2024 (Filed With SEC on February 29, 2024)

Fourth Amendment to Option and License Agreement (CD27), dated as of December 14, 2023, by and between Gigagen, Inc. and Kineta, Inc (Filed With SEC on December 15, 2023)

Form of Amendment No. 6 to Securities Purchase Agreement, dated October 13, 2023 (Filed With SEC on October 17, 2023)

Form of Pre-Funded Warrant (Filed With SEC on October 5, 2023)

Form of Common Warrant (Filed With SEC on October 5, 2023)

Form of Wainwright Warrant (Filed With SEC on October 5, 2023)

Form of Securities Purchase Agreement, dated as of October 3, 2023 (Filed With SEC on October 5, 2023)

Second Amendment to Option and License Agreement (CD27), dated as of December 21, 2022, by and between Gigagen, Inc. and the Company (Filed With SEC on August 11, 2023)

Form of Amendment No. 5 to Securities Purchase Agreement, dated July 21, 2023 (Filed With SEC on July 21, 2023)

Form of Amendment No. 4 to Securities Purchase Agreement, dated May 1, 2023 (Filed With SEC on June 2, 2023)

Second Amendment to Option and License Agreement (VISTA), dated as of May 25, 2023, by and between Gigagen, Inc. and Kineta, Inc (Filed With SEC on May 30, 2023)

Third Amendment to Option and License Agreement (CD27), dated as of May 25, 2023, by and between Gigagen, Inc. and Kineta, Inc (Filed With SEC on May 30, 2023)

Form of Pre-Funded Warrant (Filed With SEC on April 21, 2023)

Form of Common Warrant (Filed With SEC on April 21, 2023)

Form of Wainwright Warrant (Filed With SEC on April 21, 2023)

Form of Securities Purchase Agreement, dated as of April 20, 2023 (Filed With SEC on April 21, 2023)

Open Market Sale AgreementSM, dated February 10, 2023, by and between Kineta, Inc. and Jefferies LLC (Filed With SEC on February 10, 2023)

Kineta, Inc. 2022 Equity Incentive Plan and associated forms (Filed With SEC on December 22, 2022)

Separation Agreement by and between the Company and Richard Peters, dated December 16, 2022 (Filed With SEC on December 22, 2022)

Separation Agreement by and between the Company and Michael Wyzga, dated December 16, 2022 (Filed With SEC on December 22, 2022)

Separation Agreement by and between the Company and Devin Smith, dated December 16, 2022 (Filed With SEC on December 22, 2022)

Form of Amendment No. 1 to the Merger Agreement dated December 5, 2022 (Filed With SEC on December 5, 2022)

Form of Amendment No. 2 to the Securities Purchase Agreement dated December 5, 2022 (Filed With SEC on December 5, 2022)

Form of Warrant, dated December 5, 2022 (Filed With SEC on December 5, 2022)

Form of Amendment No. 2 to the Registration Rights Agreement, dated December 5, 2022 (Filed With SEC on December 5, 2022)

Form of Securities Purchase Agreement Amendment, dated October 24, 2022 (Filed With SEC on October 24, 2022)

Form of Warrant, dated October 24, 2022 (Filed With SEC on October 24, 2022)

Form of Registration Rights Agreement Amendment, dated October 24, 2022 (Filed With SEC on October 24, 2022)

Kineta, Inc. Amended and Restated 2008 Stock Plan (the Kineta 2008 Plan) and associated forms (Filed With SEC on August 29, 2022)

Kineta, Inc. 2010 Equity Incentive Plan (the Kineta 2010 Plan) and associated forms (Filed With SEC on August 29, 2022)

First Amendment to Kineta 2010 Plan (Filed With SEC on August 29, 2022)

Second Amendment to Kineta 2010 Plan (Filed With SEC on August 29, 2022)

Kineta, Inc. 2020 Equity Incentive Plan (the Kineta 2020 Plan) and associated forms (Filed With SEC on August 29, 2022)

Kineta Lease, dated as of November 19, 2010, by and between Kineta, Inc. and ARE-SEATTLE No.17, LLC (Filed With SEC on August 29, 2022)

First Amendment to Kineta Lease, dated as of August 12, 2011, by and between Kineta, Inc. and ARE-SEATTLE No.17, LLC (Filed With SEC on August 29, 2022)

Second Amendment to Kineta Lease, dated as of August 28, 2012, by and between Kineta, Inc. and ARE-SEATTLE No.17, LLC (Filed With SEC on August 29, 2022)

Third Amendment to Kineta Lease, dated as of February 28, 2013, by and between Kineta, Inc. and ARE-SEATTLE No.17, LLC (Filed With SEC on August 29, 2022)

Fourth Amendment to Kineta Lease, dated as of June 28, 2016, by and between Kineta, Inc. and ARE-SEATTLE No.17, LLC (Filed With SEC on August 29, 2022)

Fifth Amendment to Kineta Lease, dated as of June 30, 2020, by and between Kineta, Inc. and ARE-SEATTLE No.17, LLC (Filed With SEC on August 29, 2022)

Asset Purchase Agreement, dated June 5, 2022, by and among Yumanity and Janssen (Filed With SEC on June 6, 2022)

Agreement and Plan of Merger, dated June 5, 2022, by and among Yumanity, Kineta and Merger Sub (Filed With SEC on June 6, 2022)

Form of Yumanity Support Agreement, dated June 5, 2022, by and among Kineta, Yumanity and each of the parties named in each agreement therein (Filed With SEC on June 6, 2022)

Form of Kineta Support Agreement, dated June 5, 2022, by and among Yumanity, Kineta and each of the parties named in each agreement therein (Filed With SEC on June 6, 2022)

Form of Lock-up Agreement, dated June 5, 2022, by each of the parties named in each agreement therein (Filed With SEC on June 6, 2022)

Form of Securities Purchase Agreement, dated June 5, 2022, by each of the parties named therein (Filed With SEC on June 6, 2022)

Form of Registration Rights Agreement, dated June 5, 2022, by each of the parties named therein (Filed With SEC on June 6, 2022)

Lease Termination Agreement by and between Yumanity Therapeutics, Inc. and Ice Box, LLC dated as of May 16, 2022 (Filed With SEC on May 18, 2022)

Separation Agreement by and between Yumanity Therapeutics, Inc. and Ajay Verma, dated as of February 9, 2022 (Filed With SEC on May 12, 2022)

Separation Agreement by and between Yumanity Therapeutics, Inc. and Paulash Mohsen dated as of March 14, 2022 (Filed With SEC on May 12, 2022)

Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 24, 2022)

License Agreement by and between Yumanity Therapeutics, Inc. and MIL 40, LLC dated as of February 28, 2022 (Filed With SEC on March 4, 2022)

Termination Agreement by and between Yumanity Therapeutics, Inc. and MIL 40, LLC dated as of February 28, 2022 (Filed With SEC on March 4, 2022)

Employment Offer Letter by and between Yumanity Therapeutics, Inc. and Michael D. Wyzga, dated July 12, 2021 (redacted) (Filed With SEC on August 16, 2021)

Sixth Amendment and Consent to Loan and Security Agreement dated as of April 13, 2021, by and among Yumanity, Inc., the lenders party thereto and Hercules Capital, Inc (Filed With SEC on August 12, 2021)

A. Verma Offer Letter (redacted) (Filed With SEC on August 12, 2021)

D. Smith Offer Letter (redacted) (Filed With SEC on August 12, 2021)

Fifth Amendment and Consent to Loan and Security Agreement dated as of March 29, 2021, by and among Yumanity, Inc., the lenders party thereto and Hercules Capital, Inc (Filed With SEC on May 13, 2021)

Open Market Sale Agreement SM, dated April 8, 2021, by and between Yumanity Therapeutics, Inc., and Jefferies LLC (Filed With SEC on April 8, 2021)

Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 31, 2021)

Amended and Restated Warrant Agreement to Purchase Common Stock of the Company issued to Hercules Capital, Inc., dated December 22, 2020 (Filed With SEC on March 31, 2021)

Contingent Value Rights Agreement, dated as of December 22, 2020 by and among the Company and Shareholder Representative Services LLC (Filed With SEC on December 30, 2020)

Unconditional Secured Guaranty and Pledge Agreement, dated December 22, 2020 by and between the Company (formerly known as Proteostasis Therapeutics, Inc.) and Hercules Capital,... (Filed With SEC on December 30, 2020)

Fourth Amendment and Consent to Loan and Security Agreement dated as of December 22, 2020, by and among Yumanity, Inc. (formerly Yumanity Therapeutics, Inc.), the lenders party... (Filed With SEC on December 30, 2020)

Registration Rights Agreement, dated as of December 22, 2020 by among the Company (formerly known as Proteostasis Therapeutics, Inc.) and certain purchasers listed therein (Filed With SEC on December 30, 2020)

Form of Director and Officer Indemnification Agreements (Filed With SEC on December 30, 2020)

Yumanity Therapeutics, Inc. Amended and Restated 2018 Stock Option and Grant Plan and forms of award agreements thereunder (Filed With SEC on December 30, 2020)

Subscription Agreement, dated as of December 14, 2020 by and among Proteostasis Therapeutics, Inc. and the Purchasers named therein (Filed With SEC on December 15, 2020)

Form of Registration Rights Agreement (Filed With SEC on December 15, 2020)

First Amendment to Merger Agreement, dated November 6, 2020, by and among PTI, Yumanity, Holdings and Merger Sub (Filed With SEC on November 6, 2020)

Form of Support Agreement, by and between Proteostasis Therapeutics, Inc., Yumanity Therapeutics, Inc. and Yumanity Holdings, LLC (Filed With SEC on September 23, 2020)

Tangible Property and Exclusive Patent License Agreement, by and between Yumanity Therapeutics, Inc., Yumanity Holdings, LLC and Whitehead Institute for Biomedical Research, dated... (Filed With SEC on September 23, 2020)

License Agreement, by and between Yumanity Therapeutics, Inc. and MIL 40G LLC, dated as of February 5, 2020 (Filed With SEC on September 23, 2020)

Loan and Security Agreement, by and among Yumanity Therapeutics, Inc. and Hercules Capital, Inc., dated as December 20, 2019 (Filed With SEC on September 23, 2020)

Warrant Agreement to Purchase Preferred Units of Yumanity Holdings, LLC issued to Hercules Capital, Inc., dated December 20, 2019 (Filed With SEC on September 23, 2020)

U.S. Small Business Administration Paycheck Protection Program Note with Silicon Valley Bank, dated as of April 24, 2020 (Filed With SEC on September 23, 2020)

Common Unit Warrant issued to Alexandria Equities, LLC (as predecessor to Alexandria Venture Investments, LLC) on October 9, 2015 (Filed With SEC on September 23, 2020)

Common Unit Warrant issued to Redmile Capital Offshore II Master Fund, Ltd. on August 14, 2015 (Filed With SEC on September 23, 2020)

Common Unit Warrant issued to Redmile Biotechnologies Investments I AF, LP (as predecessor to Redmile Biopharma Investments I, L.P.) on August 14, 2015 (Filed With SEC on September 23, 2020)

Common Unit Warrant issued to N. Anthony Coles on August 14, 2015 (Filed With SEC on September 23, 2020)

Warrant to Purchase Limited Liability Company Interests issued to Silicon Valley Bank on June 14, 2018 (Filed With SEC on September 23, 2020)

Warrant to Purchase Limited Liability Company Interests issued to Oxford Finance LLC dated June 14, 2018 (Filed With SEC on September 23, 2020)

Agreement and Plan of Merger and Reorganization, dated August 22, 2020, by and among PTI, Yumanity, Holdings and Merger Sub (Filed With SEC on August 24, 2020)

Form of CVR Agreement by and between PTI and the CVR Rep (Filed With SEC on August 24, 2020)

Form of PTI Support Agreement, dated August 22, 2020, by and between Yumanity, PTI and each of the parties named in each agreement therein (Filed With SEC on August 24, 2020)

Form of Yumanity Support Agreement, dated August 22, 2020, by and between PTI, Yumanity and each of the parties named in each agreement therein (Filed With SEC on August 24, 2020)

Form of PTI Lock-Up Agreement, dated August 22, 2020, by each of the parties named in each agreement therein (Filed With SEC on August 24, 2020)

Form of Yumanity Lock-Up Agreement, dated August 22, 2020, by each of the parties named in each agreement therein (Filed With SEC on August 24, 2020)

Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 10, 2020)

Amended and Restated Employment Agreement between the Registrant and Ben Munoz, dated March 9, 2020 (Filed With SEC on March 10, 2020)

Amended and Restated Employment Agreement between the Registrant and Marija Zecevic, dated March 9, 2020 (Filed With SEC on March 10, 2020)

Form of Amended and Restated Executive Agreement (Filed With SEC on March 10, 2020)

Form of Executive Employment Agreement (Filed With SEC on March 10, 2020)

Separation Agreement and General Release between the Company and Po-Shun Lee, dated as of July 22, 2019 (Filed With SEC on November 7, 2019)

Consulting Agreement between the Company and Po-Shun Lee, dated as of July 23, 2019 (Filed With SEC on November 7, 2019)

Sales Agreement dated May 9, 2019 by and between Proteostasis Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on May 9, 2019)

Employment Agreement between the Company and Marija Zecevic, dated as of March 8, 2017 (Filed With SEC on March 8, 2019)

Employment Agreement between the Company and Sheila Wilson, dated as of May 18, 2017 (Filed With SEC on March 8, 2019)

Technology Transfer and License Agreement between the Company and Genentech, Inc., dated December 13, 2018 (Filed With SEC on March 8, 2019)

Assignment and Release Agreement between the Company and Cystic Fibrosis Foundation, dated December 19, 2018 (Filed With SEC on March 8, 2019)

Underwriting Agreement, dated October 23, 2018 (Filed With SEC on October 24, 2018)

Fourth Amendment to Lease dated April 13, 2018 by and between ARE-Tech Square, LLC and the Company (Filed With SEC on August 8, 2018)

First Amendment to Lease dated April 13, 2018 by and between Ice Box, LLC and the Company (Filed With SEC on August 8, 2018)

Amendment No. 6 to Collaboration and License Agreement dated April 23, 2018 by and between the Company and Astellas Pharma Inc (Filed With SEC on August 8, 2018)

Consulting Agreement dated May 7, 2018 by and between the Company and Danforth Advisors, LLC (Filed With SEC on August 8, 2018)

Offer Letter, dated August 3, 2018, by and between the Company and Sandra Zimmerman (Filed With SEC on August 8, 2018)

Sales Agreement dated March 23, 2018 by and between Proteostasis Therapeutics, Inc. and Leerink Partners LLC (Filed With SEC on March 23, 2018)

Non-Employee Director Compensation Policy (Filed With SEC on March 14, 2018)

Employment Agreement between the Company and Benito Munoz, dated as of October 17, 2016 (Filed With SEC on March 14, 2018)

Underwriting Agreement, dated December 13, 2017 (Filed With SEC on December 15, 2017)

ProteostasisTherapeutics, Inc. | 200 Technology Square, Fourth Floor, Cambridge, MA 02139 | T: 617 ###-###-#### (Filed With SEC on July 31, 2017)

Proteostasis Therapeutics, Inc. | 200 Technology Square, Fourth Floor, Cambridge, MA 02139 | T: 617 ###-###-#### (Filed With SEC on November 10, 2016)

Proteostasis Therapeutics, Inc. [] Shares Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on August 31, 2016)

Amendment No. 5 to Collaboration and License Agreement (Filed With SEC on August 15, 2016)

Proteostasis Therapeutics, Inc. | 200 Technology Square, Fourth Floor, Cambridge, MA 02139 | T: 617 ###-###-#### (Filed With SEC on August 8, 2016)

Amendment No. 4 to Collaboration and License Agreement (Filed With SEC on May 27, 2016)

CONSULTING AGREEMENT (Filed With SEC on March 21, 2016)

Proteostasis Therapeutics, Inc. | 200 Technology Square, Fourth Floor, Cambridge, MA 02139 | ###-###-#### (Filed With SEC on March 16, 2016)

Proteostasis Therapeutics, Inc. [] Shares Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on February 10, 2016)

THIRD AMENDED ANDRESTATED STOCKHOLDERS AGREEMENT (Filed With SEC on February 1, 2016)

PROTEOSTASIS THERAPEUTICS, INC. 2016 STOCKOPTION AND INCENTIVE PLAN (Filed With SEC on February 1, 2016)

PROTEOSTASIS THERAPEUTICS, INC. SENIOREXECUTIVE CASH INCENTIVE BONUS PLAN (Filed With SEC on February 1, 2016)

PROTEOSTASIS THERAPEUTICS, INC. 2016 EMPLOYEESTOCK PURCHASE PLAN (Filed With SEC on February 1, 2016)

PROTEOSTASIS THERAPEUTICS, INC. NON-EMPLOYEEDIRECTOR COMPENSATION POLICY (Filed With SEC on February 1, 2016)

Void after 5:00p.m. New York Time on the Expiration Date (as defined below) (Filed With SEC on December 23, 2015)

RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between Proteostasis Therapeutics, Inc. and Cystic FibrosisFoundation Therapeutics, Inc. Dated March 20, 2012 (Filed With SEC on December 23, 2015)

AMENDED AND RESTATED LICENSE AGREEMENT (Filed With SEC on December 23, 2015)

COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BY AND BETWEEN PROTEOSTASIS THERAPEUTICS, INC. and BIOGEN IDEC NEWVENTURES INC. December 5, 2013 (Filed With SEC on December 23, 2015)

COLLABORATION AND LICENSEAGREEMENT BETWEEN ASTELLAS PHARMA INC. AND PROTEOSTASIS THERAPEUTICS, INC. (Filed With SEC on December 23, 2015)

PROTEOSTASIS THERAPEUTICS, INC. 2008 EQUITY INCENTIVE PLAN (Filed With SEC on December 23, 2015)

LEASE AGREEMENT (Filed With SEC on December 23, 2015)

PROTEOSTASIS THERAPEUTICS, INC. FORM OF INDEMNIFICATION AGREEMENT (Filed With SEC on December 23, 2015)

PROTEOSTASIS THERAPEUTICS, INC. CONSULTING AGREEMENT (Filed With SEC on December 23, 2015)

Amendment No. 2 to Collaboration and License Agreement (Filed With SEC on December 23, 2015)

Amendment No. 3 to Collaboration and License Agreement (Filed With SEC on December 23, 2015)

Category

Industry

Companies

Contracts

PROTEOSTASIS THERAPEUTICS, INC. Contracts & Agreements